Jijo is the Chief Medical Officer for Johnson & Johnson MedTech & Interventional Oncology. In this role, he drives strong safety governance and risk management across the product lifecycle, promoting safe and effective patient outcomes. Jijo is a member of the Office of the Chief Medical Officer Senior Leadership Team and the Johnson & Johnson Interventional Oncology Senior Leadership Team. Previously, Jijo was the Chief Medical Officer for the Johnson & Johnson Family of Consumer Companies, now known as Kenvue, where he led the Safety Council for the Consumer sector and was a member of the Consumer R&D Leadership Team. From 2021-2023 he served as the Chair of the Board of Directors of the Medical Device Innovation Consortium (MDIC) and continues to serve as an active member on the organization’s board of directors.
Before joining Johnson & Johnson in 2014, Jijo spent six years at Pfizer Inc. Prior to that, from 2009 to 2012 he lived in Bangalore, India, where he was the head of the therapeutic area that included OTC, Enbrel and Active Moiety within Worldwide Safety and Regulatory, in addition to having responsibility for regional safety and regulatory oversight.
He received his medical degree from St. John’s Medical College in India and later earned a Master of Public Health degree in Population and Family Studies from the Joseph L. Mailman School of Public Health, Columbia University, New York City.